New Emerging Roles of MicroRNAs in Breast Cancer
Overview
Affiliations
Background: MicroRNAs constitute a large family of non-coding RNAs, which actively participate in tumorigenesis by regulating a set of mRNAs of distinct signaling pathways. An altered expression of these molecules has been found in different tumorigenic processes of breast cancer, the most common type of cancer in the female population worldwide.
Purpose: The objective of this review is to discuss how miRNAs become master regulators in breast tumorigenesis.
Methods: An integrative review of miRNAs and breast cancer literature from the last 5 years was done on PubMed. We summarize recent works showing that the defects on the biogenesis of miRNAs are associated with different breast cancer characteristics. Then, we show several examples that demonstrate the link between cellular processes regulated by miRNAs and the hallmarks of breast cancer. Finally, we examine the complexity in the regulation of these molecules as they are modulated by other non-coding RNAs and the clinical applications of miRNAs as they could serve as good diagnostic and classification tools.
Conclusion: The information presented in this review is important to encourage new directed studies that consider microRNAs as a good tool to improve the diagnostic and treatment alternatives in breast cancer.
Non-Coding RNAs Extended Omnigenic Module of Cancers.
Li J, Wang B, Ma X Entropy (Basel). 2024; 26(8).
PMID: 39202109 PMC: 11353529. DOI: 10.3390/e26080640.
Lambrechts Y, Garg A, Floris G, Punie K, Neven P, Nevelsteen I Genes Immun. 2023; 24(5):270-279.
PMID: 37759086 PMC: 10575765. DOI: 10.1038/s41435-023-00220-z.
Tumor Suppressor Candidate 2 (TUSC2): Discovery, Functions, and Cancer Therapy.
Arrigo A, Regua A, Najjar M, Lo H Cancers (Basel). 2023; 15(9).
PMID: 37173921 PMC: 10177220. DOI: 10.3390/cancers15092455.
Abbate J, Arfuso F, Riolo K, Capparucci F, Brunetti B, Lanteri G Animals (Basel). 2023; 13(6).
PMID: 36978627 PMC: 10044548. DOI: 10.3390/ani13061086.
The role of miR-128 in cancer development, prevention, drug resistance, and immunotherapy.
Setia Budi H, Younus L, Hadi Lafta M, Parveen S, Mohammad H, Al-Qaim Z Front Oncol. 2023; 12:1067974.
PMID: 36793341 PMC: 9923359. DOI: 10.3389/fonc.2022.1067974.